SGX Inks Research Collaborations with Millennium, Aventis | GenomeWeb

SAN FRANCISCO, Jan. 8 - Millennium Pharmaceuticals has struck a deal with Structural Genomix in which SGX will help Millennium sift through its library of drug targets, SGX said here on Tuesday.

SGX also said it has partnered with Aventis Pharmaceuticals to help it identify its own lead compounds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.